Drug intelligence / Profile preview

EA501

Development stage: Preclinical
Lead developer: Suzhou Bowei Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal, Ophthalmic

Overview

EA501 is a preclinical-stage monoclonal antibody being developed by Neathera (also known as Shanghai EA Therapeutics or Shandong Lanyi Pharmaceutical Technology) for the treatment of ophthalmologic conditions, including diabetic eye disease, age-related macular degeneration (AMD), and geographic atrophy. The drug is designed to modulate both the complement pathway and angiogenesis, addressing key pathological drivers of retinal diseases. EA501 is currently in preclinical development, with Phase I/II clinical trials targeted to begin in 2027.

Beyond the preview

Go deeper on EA501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EA501.